Tybost
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $73,094 | 13 | 0 |
| 2023 | $45,412 | 23 | 0 |
| 2022 | $9,536 | 14 | 0 |
| 2021 | $46,857 | 20 | 0 |
| 2020 | $59,677 | 27 | 0 |
| 2019 | $54,496 | 50 | 0 |
| 2018 | $101,286 | 67 | 0 |
| 2017 | $160,852 | 63 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $551,209 | 277 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants | Gilead Sciences, Inc. | $289,071 | 0 |
| A Phase 2/3, Multicenter, Open-label, Multicohort, Two Part Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat boosted Darunavir (DRV/co), Administered with a Background Regimen (BR) in HIV-1 Infected, Treatment-Experienced, Virologically Suppressed Pediatric Subjects | Gilead Sciences Inc | $156,779 | 0 |
| A Phase 2/3, Multicenter, Open-label, Multicohort, Two Part Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat boosted Darunavir (DRV/co), Administered with a Background Regimen (BR) in HIV-1 Infected, Treatment-Experienced, Virologically Suppressed Pediatric Subjects | Gilead Sciences, Inc. | $100,190 | 0 |
| A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Disoproxil Fumarate in HIV 1 Infected, Antiretroviral Treatment-Naive Adults | Gilead Sciences Inc | $3,873 | 0 |
| A Phase 3b, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir Plus Two Fully Active Nucleoside Reverse Transcriptase Inhibitors in HIV 1 Infected, Antiretroviral Treatment-Naive and Experienced Adults with No DRV Resistance-associated Mutations | Gilead Sciences, Inc. | $1,096 | 0 |
| A Phase 3b, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Cobicistat-boosted Darunavir Plus Two Fully Active Nucleoside Reverse Transcriptase Inhibitors in HIV 1 Infected, Antiretroviral Treatment-Naive and Experienced Adults with No DRV Resistance-associated Mutations | Gilead Sciences Inc | $200.00 | 0 |
Top Doctors Receiving Payments for Tybost
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Los Angeles, CA | $551,209 | 277 |
Manufacturing Companies
- Gilead Sciences, Inc. $390,357
- Gilead Sciences Inc $160,852
Product Information
- Type Drug
- Total Payments $551,209
- Total Doctors 0
- Transactions 277
About Tybost
Tybost is a drug associated with $551,209 in payments to 0 healthcare providers, recorded across 277 transactions in the CMS Open Payments database. The primary manufacturer is Gilead Sciences Inc.
Payment data is available from 2017 to 2024. In 2024, $73,094 was paid across 13 transactions to 0 doctors.
The most common payment nature for Tybost is "Unspecified" ($551,209, 100.0% of total).
Tybost is associated with 6 research studies, including "A Phase 2/3, Multicenter, Open-label, Multicohort Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected, Virologically Suppressed Pediatric Participants" ($289,071).